

# Alejandro LÃ³pez-Soto

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5439715/publications.pdf>

Version: 2024-02-01

50  
papers

3,792  
citations

201674

27  
h-index

223800

46  
g-index

51  
all docs

51  
docs citations

51  
times ranked

7136  
citing authors

#	ARTICLE	IF	CITATIONS
1	LAG-3 Blockade with Relatlimab (BMS-986016) Restores Anti-Leukemic Responses in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 2112.	3.7	62
2	BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 1766.	3.7	27
3	A cytofluorimetric assay to evaluate intracellular cytokine production by NK cells. <i>Methods in Enzymology</i> , 2020, 631, 343-355.	1.0	8
4	Daratumumab is a safe and effective rescue therapy for multiple myeloma patients who relapse after allo-HSCT. <i>Bone Marrow Transplantation</i> , 2020, 55, 461-463.	2.4	3
5	Evaluation of NK cell cytotoxic activity against malignant cells by the calcein assay. <i>Methods in Enzymology</i> , 2020, 631, 483-495.	1.0	10
6	Mechanisms of Apoptosis Resistance to NK Cell-Mediated Cytotoxicity in Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3726.	4.1	61
7	Editorial: Dendritic Cell-Based Immunotherapy in Solid and Haematologic Tumors. <i>Frontiers in Immunology</i> , 2020, 11, 507.	4.8	5
8	Mechanisms of Resistance to NK Cell Immunotherapy. <i>Cancers</i> , 2020, 12, 893.	3.7	34
9	The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling. <i>Frontiers in Immunology</i> , 2019, 10, 2455.	4.8	4
10	WNT Signaling in Cancer Immunosurveillance. <i>Trends in Cell Biology</i> , 2019, 29, 44-65.	7.9	168
11	NK Cell-Based Immunotherapy in Cancer Metastasis. <i>Cancers</i> , 2019, 11, 29.	3.7	82
12	CD107a Degranulation Assay to Evaluate Immune Cell Antitumor Activity. <i>Methods in Molecular Biology</i> , 2019, 1884, 119-130.	0.9	43
13	A Flow Cytometric NK Cell-Mediated Cytotoxicity Assay to Evaluate Anticancer Immune Responses In Vitro. <i>Methods in Molecular Biology</i> , 2019, 1884, 131-139.	0.9	6
14	Immunosurveillance of cancer cell stress. <i>Cell Stress</i> , 2019, 3, 295-309.	3.2	10
15	Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia. <i>Frontiers in Immunology</i> , 2018, 9, 2917.	4.8	35
16	Cancer-Induced Endoplasmic Reticulum Stress in T Cells Subverts Immunosurveillance. <i>Cell Metabolism</i> , 2018, 28, 803-805.	16.2	4
17	The hallmarks of successful anticancer immunotherapy. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	419
18	NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines. <i>Cancer Research</i> , 2018, 78, 3913-3925.	0.9	53

#	ARTICLE	IF	CITATIONS
19	Involvement of autophagy in NK cell development and function. <i>Autophagy</i> , 2017, 13, 633-636.	9.1	27
20	Biallelic IRF8 Mutations Causing NK Cell Deficiency. <i>Trends in Molecular Medicine</i> , 2017, 23, 195-197.	6.7	2
21	NKG2D Signaling: The Immune Subversive Side of HDAC3. <i>Trends in Immunology</i> , 2017, 38, 151-153.	6.8	0
22	IFN Signaling and ICB Resistance: Time is on Tumor's Side. <i>Trends in Cancer</i> , 2017, 3, 161-163.	7.4	14
23	Immunosurveillance of Malignant Cells with Complex Karyotypes. <i>Trends in Cell Biology</i> , 2017, 27, 880-884.	7.9	12
24	Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia. <i>Oncolmmunology</i> , 2017, 6, e1353856.	4.6	14
25	Control of Metastasis by NK Cells. <i>Cancer Cell</i> , 2017, 32, 135-154.	16.8	549
26	Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade. <i>Oncolmmunology</i> , 2017, 6, e1346766.	4.6	21
27	Immune and inflammatory responses to DNA damage in cancer and aging. <i>Mechanisms of Ageing and Development</i> , 2017, 165, 10-16.	4.6	32
28	The Molecular Basis of the Immune Response to Stressed Cells and Tissues. , 2016, , 53-79.		0
29	Carcinoma's astrocyte gap junctions promote brain metastasis by cGAMP transfer. <i>Nature</i> , 2016, 533, 493-498.	27.8	677
30	Drug-induced hyperploidy stimulates an antitumor NK cell response mediated by NKG2D and DNAM-1 receptors. <i>Oncolmmunology</i> , 2016, 5, e1074378.	4.6	36
31	Caspases Connect Cell-Death Signaling to Organismal Homeostasis. <i>Immunity</i> , 2016, 44, 221-231.	14.3	279
32	Pleiotropic Anti-Angiogenic and Anti-Oncogenic Activities of the Novel Mithralog Demycarosyl-3D-ÅY-D-Digitoxosyl-Mithramycin SK (EC-8042). <i>PLoS ONE</i> , 2015, 10, e0140786.	2.5	11
33	NKG2D signaling in cancer immunosurveillance. <i>International Journal of Cancer</i> , 2015, 136, 1741-1750.	5.1	109
34	Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	51
35	Molecular Bases for the Regulation of NKG2D Ligands in Cancer. <i>Frontiers in Immunology</i> , 2014, 5, 106.	4.8	52
36	Expansion of NK Cells and Reduction of NKG2D Expression in Chronic Lymphocytic Leukemia. Correlation with Progressive Disease. <i>PLoS ONE</i> , 2014, 9, e108326.	2.5	69

#	ARTICLE	IF	CITATIONS
37	Epithelialâ€“Mesenchymal Transition Induces an Antitumor Immune Response Mediated by NKG2D Receptor. <i>Journal of Immunology</i> , 2013, 190, 4408-4419.	0.8	89
38	Regulation of NKG2D signaling during the epithelial-to-mesenchymal transition. <i>Onc Immunology</i> , 2013, 2, e25820.	4.6	11
39	Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1201-1210.	4.2	44
40	Conceptual aspects of self and nonself discrimination. <i>Self/nonself</i> , 2011, 2, 19-25.	2.0	27
41	NK cell immune recognition. , 2010, , 65-77.		1
42	Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 1829-1836.	1.3	73
43	Comment on â€œProteasome Regulation of ULBP1 Transcriptionâ€• <i>Journal of Immunology</i> , 2009, 183, 4145.1-4145.	0.8	0
44	HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. <i>Oncogene</i> , 2009, 28, 2370-2382.	5.9	107
45	Papel de MICA en la patogenia de la artritis reumatoide. <i>Seminarios De La Fundaci3n Espaola De Reumatologaa</i> , 2008, 9, 77-85.	0.1	0
46	The NKG2D receptor: sensing stressed cells. <i>Trends in Molecular Medicine</i> , 2008, 14, 179-189.	6.7	103
47	NKG2D ligands: key targets of the immune response. <i>Trends in Immunology</i> , 2008, 29, 397-403.	6.8	218
48	MHC class I chain-related gene B (MICB) is associated with rheumatoid arthritis susceptibility. <i>Rheumatology</i> , 2007, 46, 426-430.	1.9	35
49	MHC Class I Chain-Related Gene B Promoter Polymorphisms and Celiac Disease. <i>Human Immunology</i> , 2006, 67, 208-214.	2.4	29
50	Transcriptional Regulation of ULBP1, a Human Ligand of the NKG2D Receptor. <i>Journal of Biological Chemistry</i> , 2006, 281, 30419-30430.	3.4	54